Clinical Data IDEAYA/Servier PKC drug aces uveal melanoma trial PharmaphorumServier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026. Clinical DataOncologyRead full story Post navigation Previous: AbbVie enters world of pain in up to $715M deal with China’s HaiscoNext: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026